The expectation of treating Covid-19 with an obsessive-compulsive disorder

Although Covid-19 vaccine has been vaccinated to protect people, the health sector globally is continuing to work on available drugs to treat the disease. Among them, scientists found that the antidepressant used to treat obsessive-compulsive disorder (OCD) may also be effective in treating some cases of Covid-19.

The drug fluvoxamine, commonly sold under the brand name Luvox, has emerged as a bright spot in the early treatment of Covid-19 with studies showing it can prevent some symptoms from developing. Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI), which changes the way chemicals are used by nerves in the human brain.

These chemicals are called neurotransmitters, and are released by the body’s nerves before attaching to other nerves. Experts believe that an imbalance in neurotransmitters can cause mental disorders such as depression. Fluvoxamine was approved by the Food and Drug Administration (FDA) to treat OCD in 1994, but is also used to treat patients with social anxiety, post-traumatic stress, and confusion. binge eating disorder and gambling disease.

Fluvoxamine, commonly sold under the brand name Luvox, can prevent Covid-19 from worsening and minimize symptoms after 2 weeks. (Illustration)

A 2005 analysis published in the journal Neuropsychiatric Disease and Treatment found that the drug was quite well tolerated and that the most frequently reported side effect was nausea. Research says it has no significant effect on body weight or cardiovascular performance.

Scientists have hypothesized that this drug may also be helpful in treating Covid-19 patients with severe symptoms. Results of a two-week randomized clinical trial conducted last November, by scientists at the University of Washington in St. Petersburg Louis showed no deterioration in the conditions of dozens of Covid-19 patients treated with fluvoxamine.

In the study led by Eric Lenze of the School of Psychiatry, a total of 115 people completed the trial. Clinical deterioration did not occur in 80 patients in the fluvoxamine group and in 6/72 patients in the placebo group. The fluvoxamine group had serious side effects and 11 other side effects, while the placebo group had 6 serious side effects and 12 other side effects.

The results are published in the Journal of the American Medical Association. DBased on his previous small-scale experiment, Lenze is conducting extensive research to try and determine the efficacy of fluvoxamine in the treatment of early COVID.

Gout medications are expected to be able to combat the symptoms of Covid-19( – A drug to treat gout is being tested by researchers in the UK with the hope of fighting Covid-19 and reducing the time to recover from the disease.

In the trial led by Dr. David Seftel and scientist David Boulware of the University of Minnesota Medical School, 65 used fluvoxamine and 48 people declined. Fluvoxamine appears to be promising as an early Covid-19 treatment to prevent deterioration requiring hospitalization and minimize symptoms that may persist after 2 weeks, the authors conclude. There is more evidence of “randomized trial”.

“Fluvoxamine may benefit patients with COVID-19 by slowing the progression of symptoms. It’s safe, cheap, and FDA approved. Use FDA-approved drugs for a new purpose.” , repositioning drugs, used to test new treatments faster than the development of new drugs, ” said a FAQ website.

Manager National Institutes of Health (NIH) stated: “FDA will have a duty to figure out whether the use of this drug should be approved. Its benefits and risks will go hand in hand. The benefit is that fluvoxamine may even be possible.” There is a 20% reduction in the chance that people will be hospitalized, which is probably a good thing to be added to. “

Huong Giang (Source: Newsweek)



Leave a Reply

Your email address will not be published. Required fields are marked *